 | Up a level |
Terwijn, M.; van Putten, W. L. J.; Kelder, A.; van der Velden, V. H. J.; Brooimans, R. A.; Pabst, T.; Maertens, J.; Boeckx, N.; de Greef, G. E.; Valk, P. J. M.; Preijers, F. W. M. B.; Huijgens, P. C.; Drager, A. M.; Schanz, U.; Jongen-Lavrecic, M.; Biemond, B. J.; Passweg, J. R.; van Gelder, M.; Wijermans, P.; Graux, C.; ... (2013). High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of clinical oncology, 31(31), pp. 3889-3897. American Society of Clinical Oncology 10.1200/JCO.2012.45.9628
Schlenk, R. F.; Taskesen, E.; van Norden, Y.; Krauter, J.; Ganser, A.; Bullinger, L.; Gaidzik, V. I.; Paschka, P.; Corbacioglu, A.; Gohring, G.; Kundgen, A.; Held, G.; Gotze, K.; Vellenga, E.; Kuball, J.; Schanz, U.; Passweg, J.; Pabst, Thomas; Maertens, J.; Ossenkoppele, G. J.; ... (2013). The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood, 122(9), pp. 1576-1582. American Society of Hematology 10.1182/blood-2013-05-503847
